Milestone Pharmaceuticals Inc. Financing Cash Flow
Milestone Pharmaceuticals Inc. (MIST) reported Financing Cash Flow of $103.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $9.13M, a 25269.44% increase year-over-year.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $94.35M, a 67295.71% increase year-over-year.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $36.43M, a 151704.17% increase year-over-year.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $48.92M, a 66005.41% increase year-over-year.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2025 was $85.53M, a 166.28% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2024 was $32.12M, a 32.79% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2023 was $47.79M, a 1447.67% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2022 was $3.09M, a 38.91% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $103.49M 10-Q · filed 2026-08-12 | $139.92M derived: sum of 3 quarters · filed 2026-08-12 | $188.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $94.35M 10-Q · filed 2026-05-13 | $130.79M derived: sum of 2 quarters · filed 2026-05-13 | $179.71M derived: sum of 3 quarters · filed 2026-05-13 | $179.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $36.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $85.35M derived: sum of 2 quarters · filed 2026-03-20 | $85.39M derived: sum of 3 quarters · filed 2026-08-12 | $85.53M 10-K · filed 2026-03-20 |
| 2025-09-30 | $48.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $48.95M derived: sum of 2 quarters · filed 2026-08-12 | $49.09M 10-Q · filed 2025-11-12 | $49.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $176.00K 10-Q · filed 2026-08-12 | $200.00K derived: sum of 3 quarters · filed 2026-08-12 | $274.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $140.00K 10-Q · filed 2026-05-13 | $164.00K derived: sum of 2 quarters · filed 2026-05-13 | $238.00K derived: sum of 3 quarters · filed 2026-05-13 | -$60.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $98.00K derived: sum of 2 quarters · filed 2026-03-20 | -$200.00K derived: sum of 3 quarters · filed 2026-03-20 | $32.12M 10-K · filed 2026-03-20 |
| 2024-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$224.00K derived: sum of 2 quarters · filed 2025-11-12 | $32.09M 10-Q · filed 2025-11-12 | $32.10M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $32.02M 10-Q · filed 2025-08-12 | $32.02M derived: sum of 3 quarters · filed 2025-08-12 | $32.33M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $32.32M 10-Q · filed 2025-05-14 | $32.32M derived: sum of 2 quarters · filed 2025-05-14 | $32.63M derived: sum of 3 quarters · filed 2025-05-14 | $29.86M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $306.00K derived: sum of 2 quarters · filed 2025-03-13 | -$2.46M derived: sum of 3 quarters · filed 2025-03-13 | $47.79M 10-K · filed 2025-03-13 |
| 2023-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.46M derived: sum of 2 quarters · filed 2024-11-12 | $47.79M 10-Q · filed 2024-11-12 | $48.02M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $47.49M 10-Q · filed 2024-08-08 | $47.71M derived: sum of 3 quarters · filed 2024-08-08 | $50.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $50.25M 10-Q · filed 2024-05-13 | $50.48M derived: sum of 2 quarters · filed 2024-05-13 | $53.15M derived: sum of 3 quarters · filed 2024-05-13 | $53.29M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.90M derived: sum of 2 quarters · filed 2024-03-21 | $3.04M derived: sum of 3 quarters · filed 2024-03-21 | $3.09M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.81M derived: sum of 2 quarters · filed 2023-11-13 | $2.86M 10-Q · filed 2023-11-13 | $2.95M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $189.00K 10-Q · filed 2023-08-10 | $281.00K derived: sum of 3 quarters · filed 2023-08-10 | $305.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-11 | $141.00K derived: sum of 2 quarters · filed 2023-05-11 | $165.00K derived: sum of 3 quarters · filed 2023-05-11 | $5.08M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $116.00K derived: sum of 2 quarters · filed 2023-03-29 | $5.04M derived: sum of 3 quarters · filed 2023-03-29 | $5.05M 10-K · filed 2023-03-29 |
| 2021-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.94M derived: sum of 2 quarters · filed 2022-11-10 | $4.96M 10-Q · filed 2022-11-10 | $53.12M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.94M 10-Q · filed 2022-08-10 | $53.10M derived: sum of 3 quarters · filed 2022-08-10 | $77.91M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-12 | $48.18M derived: sum of 2 quarters · filed 2022-05-12 | $72.99M derived: sum of 3 quarters · filed 2022-05-12 | $73.17M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $48.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $72.97M derived: sum of 2 quarters · filed 2022-03-24 | $73.15M derived: sum of 3 quarters · filed 2022-03-24 | $73.22M 10-K · filed 2022-03-24 |
| 2020-09-30 | $24.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $24.99M derived: sum of 2 quarters · filed 2021-11-12 | $25.07M 10-Q · filed 2021-11-12 | $25.09M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $249.00K 10-Q · filed 2021-08-11 | $270.00K derived: sum of 3 quarters · filed 2021-08-11 | -$461.00K derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $77.00K 10-Q · filed 2021-05-17 | $98.00K derived: sum of 2 quarters · filed 2021-05-17 | -$633.00K derived: sum of 3 quarters · filed 2021-05-17 | $85.46M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$710.00K derived: sum of 2 quarters · filed 2021-03-29 | $85.38M derived: sum of 3 quarters · filed 2021-03-29 | $85.41M 10-K · filed 2021-03-29 |
| 2019-09-30 | -$731.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $85.36M derived: sum of 2 quarters · filed 2020-11-13 | $85.39M 10-Q · filed 2020-11-13 | $165.46M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $86.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $86.12M 10-Q · filed 2020-08-12 | $166.19M derived: sum of 3 quarters · filed 2020-10-23 | $166.19M derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | $25.00K 10-Q · filed 2020-05-14 | $80.10M derived: sum of 2 quarters · filed 2020-10-23 | $80.10M derived: sum of 3 quarters · filed 2020-10-23 | $80.11M derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $80.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $80.08M derived: sum of 2 quarters · filed 2020-10-23 | $80.08M derived: sum of 3 quarters · filed 2020-10-23 | $80.11M 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $7.00K derived: sum of 2 quarters · filed 2019-11-13 | $37.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $37.00K 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $30.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |